Ophthalmology Grand Rounds

Frank Tsai, MD February 16, 2012

- CC: "seeing a dark spot"
- HPI:

46 yo AA male Hx HTN c/o dark spot in vision OD,x3-4 weeks, constant1 month Hx bilateral periorbital fullness OD>OS

Denies eye pain, flashes, floaters Denies SOB, cough, trauma

- PMHx: HTN
- Meds: metoprolol, HCTZ
- POHx: denies
- Gtts: none
- FHx: neg glc/blindness
- SHx: +smoking ½ 1 ppd, social drinking, from North Carolina, was in National Guard
- NKDA

- Dva sc: 20/30 OD 20/30 OS
- MRx: +0.25 -0.50 x90 \rightarrow 20/30+ OD +0.50 -0.75 x110 \rightarrow 20/20- OS
- Pupils: 4-2 ou no apd
- CVF: full ou
- Color: 10/10 ou
- Red-desat: +OD (orange)
- Tapp: 18/18 at 2:15pm

- BP 157/107, HR 79, RR 20, 100% on RA, Tc 97.9
- Gross/EOM: photo
- HEENT: CN III-XII intact













• <u>SLE</u>:

LLA: no lid lag K: clear ou, no evidence exposure keratopathy AC: d/q ou IP: r/r ou, no nvi L: clear ou

• <u>DFE</u>:

Vit: clear ou ON: 0.2 severe disc edema w blurred margins & peripapillary hemes OD, 0.3 pink with mild disc edema OS Mac: flat ou BV/P: wnl ou, no vasculitis, heme, tears, holes





Differential Diagnosis

- Lymphoproliferative disease
 - Lymphoid hyperplasia
 - Lymphoma
 - Multiple myeloma
- Idiopathic
 - Idiopathic inflammatory pseudotumor
 - Sarcoidosis
- Infectious
 - Tuberculosis


Next Step?


- Labs:
 - ACE, lysozyme
 - PPD
- Imaging
 - CXR
 - Orbits
- Lumbar puncture

Medical Knowledge

 Labs: ACE serum: 56(个) Lysozyme: 15(个)


CBC, BMP, TFTs, CRP, C-ANCA, PPD WNL





Patient Care, Interpersonal & Communication Skills






• LP: Opening Pressure 24 (nml 5-20mmHg) ACE 3 Protein 42 Glucose 85 WBC 10 (nml <5mm3) **Cultures** neg Cytology neg

Transbronchial biopsy

Non-necrotizing granulomas, negative for AFB and fungi Consistent with sarcoidosis



Recap

- 46yo M Hx HTN c/o dark spot in vision OD
- Exam reveals:
 - bilateral lacrimal gland enlargement OD>OS w superior orbital spillover OD
 - hypoglobus OD
 - disc edema OD>OS
 - nasal HVF defects OD>OS

Neurosarcoidosis

Epidemiology and Etiology

- Sarcoidosis estimated 15 per 100,000 people More common in blacks
- 5-15% develop neurosarcoidosis (NS)
 50% patients present with NS at the time sarcoidosis first diagnosed
- Etiology likely multifactorial (immune, familial, environmental)

Clinical Manifestations

- Uveitis (25%; ant>int>post)
- Cranial neuropathy--most common presentation
 - Facial--most frequently involved
 - Trigeminal
 - Oculomotor
 - Optic nerve
 - Abducens
 - Vestibular
 - Vagus
 - Others

- Peripheral neuropathy
- Granulomatous infiltration of the CNS
 - Seizure
 - Psychiatric symptoms
 - Space-occupying feature
 - Neuroendocrine dysfucntion
- Idiopathic communicating hydrocephalus
- Aseptic meningitis

Diagnostic Labs

- Serum ACE (elevated 5-50%)
- Serum interleukin-2 receptor (IL2R)
 - Measure of T-cell activation, also elevated in lymphoma
 - Preferred for monitoring disease activity

Diagnostic Imaging

- MRI preferred neuro imaging, most sensitive
- High resolution CT preferred for chest
- Whole-body gallium scan or fluorodeoxyglucose (FDG) PET scan can be utilized to find inflammation or neoplasia
 - insensitive for CNS involvement and limited by poor specificity (particularly sarcoidosis vs lymphoma)

Lumbar Puncture and Biopsy

- CSF abnormalities usually non-specific; may have elevations of ACE, IgG, oligoclonal bands, CD4:CD8 lymphocyte ratios, lysozyme, B2-microglobulin levels
 CSF-ACE may be used to monitor disease activity
- Caution with LP as patients may have elevated ICP
- Conjunctival, transbronchial, skin, lymph node, peripheral nerve biopsy
 - Demonstrating non-caseating granulomas

Spaide RF, Ward DL. Conjunctival biopsy in the diagnosis of sarcoidosis. (MEE 1990)

- Prospective study of 47 sarcoidosis suspects comparing transbronchial lung biopsy (TBBX) and conjunctival biopsy (CBX)--35 AA, 12 Caucasian
- 77.1% TBBX vs 45.7% CBX positive in the AA patients 33.3% TBBX vs 25% CBX positive in Caucasian patients
- TBBX positive in pts with pulmonary infiltrates 80.6% (vs 37.5% without)
- CBX more likely to be positive in patients with pulmonary infiltrates (51.6% vs 23.1%)
- CBX positive <u>with conjunctival follicles</u> **66.7**% (vs 31.4% without), and **60**% with any ocular abnormality consistent with sarcoidosis (vs 25.9%)

Treatment

- Corticosteroids first line
 - Neuropathy treated with 0.5 mg/kg/day x4 weeks
 - Encephalopathy/vasculopathy with 1.0-1.5 mg/kg/day x4 weeks
 - Then slow taper by 5mg every 2 weeks as tolerated
 - If recurs, double the dose or give at least 10-20mg/day

Treatment

- Immunomodulating agents for refractory disease
- Mycophenolate mofetil effective for CNS
- Cyclosporine dosed at renal transplant levels
- Azathioprine, chlorambucil, cyclophosphamide targeted to lower total WBC count to 3500 or lymphocyte count to 1000 per mm3
- Radiation therapy for refractory disease

Prognosis

- 2/3rd monophasic illness
- May have relapsing –remitting course or progressive disease
- Approximately 10% die as a result from inflammatory process or its treatment


Patient Update


- Admitted for IV steroids, discharged on prednisone 60mg PO with taper
- Started azathioprine 100mg PO daily with prednisone 20mg PO daily
- Following up with rheumatology this week

Patient Update










Patient Update



Fundus Photos – after inpt steroids




Reflective Practice

- **Patient Care**: This patient was appropriately evaluated by physical examination, imaging, and testing. Patient received appropriate counseling and treatment for his ocular diseases.
- Medical Knowledge: This presentation provides an overview of neurosarcoidosis, including associated manifestations.
- **Practice-Based Learning and Improvement**: This presentation included information regarding the evaluation, differential diagnoses, and evidence-based management of patients with neurosarcoidosis.
- Interpersonal and Communication Skills: The patient was appropriately counseled on the associated disease manifestations of neurosarcoidosis. Treatment options were explained, follow-up was maintained.
- **Professionalism**: Patient was treated appropriately and with due urgency at KCHC over the course of several months.
- **Systems-Based Practice**: Appropriate care was provided via the services of neurology, radiology, pathology, rheumatology, ENT, and ophthalmology.

Thank You

Dr. Shinder Dr. EC Lazzaro Dr. Scott Dr. Asoma Dr. Thode Dr. Mostafavi Our patient



References

- 1. Stern BJ. "Neurologic sarcoidosis." UpToDate. Ed. Michael Aminoff, Talmadge King. Jan 2012.
- 2. King TE. "Clinical manifestations and diagnosis of sarcoidosis." UpToDate. Ed. Kevin Flaherty. Jan 2012.
- 3. Hoitsma E, Drent M, Sharma O. A pragmatic approach to diagnostic neurosarcoidosis in the 21st century. Curr Opin Pulm Med 2010; 16:472-479.
- 4. Menezo V, Lobo A, Yeo T, Bois R, Lightman S. Ocular features in neurosarcoidosis. Ocul Imm & Inf 2009; 17:170-178.
- 5. Spaide RF, Ward DL. Conjunctival biopsy in the diagnosis of sarcoidosis. Br J Ophthalmol 1990; 74:469-4712.